Últimas noticias sobre BlackSky Technology (NYSE:BKSY) Bolsa

BlackSky Technology

BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and from other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BlackSky Technology Inc. Class A Common Stock

BKSY

HYZN

MTRX

ORCL

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: ORCL, BKSY, AVO, HYZN y MTRX.

5 acciones en el foco este lunes: ORCL, BKSY, AVO, HYZN y MTRX

BlackSky Technology Inc

BlackSky Technology Inc. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock

Wells Fargo analyst Christian Wetherbee maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Equal-Weight and raises the price target from $305 to $320.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on FedEx, Raises Price Target to $320

During the last three months, 4 analysts shared their evaluations of Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.36, a high estimate of $10.50, and a low estimate of $8.20. This upward trend is evident, with the current average reflecting a 4.0% increase from the previous average price target of $9.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734703241_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Legacy Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$8.75</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.75</td>
<td>$8.25</td>
</tr>
<tr>
<td>Jeff Cohen</td>
<td>Ladenburg Thalmann</td>
<td>Announces</td>
<td>Buy</td>
<td>$8.20</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legacy Education. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Legacy Education compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Legacy Education's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Legacy Education's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LGCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Legacy Education analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Legacy Education: A Closer Look</h2>
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
<h3>Breaking Down Legacy Education's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Legacy Education's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 35.09%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Legacy Education's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Legacy Education's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Legacy Education's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.88%, the company showcases efficient use of assets and strong financial health.
Debt Management: Legacy Education's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.29.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGCY

4 Analysts Have This To Say About Legacy Education

NFLX

Netflix Secures Exclusive U.S. Rights To FIFA Women's World Cup For 2027 And 2031, Covering All Languages With English And Spanish Telecasts

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 7.58% since its last report. The company recently reported that it has 16.31 million shares sold short, which is 3.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CNC) - Analyzing Centene's Short Interest

During the last three months, 11 analysts shared their evaluations of Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $209.73, along with a high estimate of $245.00 and a low estimate of $184.00. This current average represents a 14.08% decrease from the previous average price target of $244.09. 
<img src="https://www.benzinga.com/files/images/story/2024/1734703219_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Cintas's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$184.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$202.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Adjusts</td>
<td>Hold</td>
<td>$200.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$236.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$191.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$215.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$209.00</td>
<td>$194.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cintas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cintas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cintas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cintas's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cintas analyst ratings.</a>
<h2>Get to Know Cintas Better</h2>
Cintas has roots tracing back to 1929, during which the Farmer family cleaned and re-sold dirty rags to manufacturing plants in Ohio. The firm has grown its business organically and through acquisitions, and today Cintas acts as a one-stop outsourcing partner for businesses. Cintas will design, manufacture, collect, and clean every employee uniform for a small weekly sum, taking on the upfront capital expense itself. In the same stop, Cintas can also replace soiled or depleted mats, mops, trash liners, towels, first aid, fire, and cleaning products. Businesses value an outsourcing partner like Cintas as it simplifies operations and leaves noncore tasks with high regulatory standards in the hands of professionals.
<h3>Cintas: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Cintas showcased positive performance, achieving a revenue growth rate of 6.8% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Cintas's ROE stands out, surpassing industry averages. With an impressive ROE of 10.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cintas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cintas's debt-to-equity ratio is below the industry average. With a ratio of 0.71, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTAS

Cintas Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Applied Optoelectronics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NYSE">AAOI</a>) short percent of float has fallen 5.67% since its last report. The company recently reported that it has 9.27 million shares sold short, which is 21.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied Optoelectronics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied Optoelectronics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Applied Optoelectronics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied Optoelectronics's peer group average for short interest as a percentage of float is 6.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AAOI

Peering Into Applied Optoelectronics's Recent Short Interest

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Market Perform and lowers the price target from $215 to $167.

HLNE

Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $167

TransMedics Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NYSE">TMDX</a>) short percent of float has risen 3.5% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 33.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransMedics Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703212_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransMedics Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TransMedics Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransMedics Gr's peer group average for short interest as a percentage of float is 7.75%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TMDX

Looking Into TransMedics Gr's Recent Short Interest

Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) has outperformed the market over the past 10 years by 4.38% on an annualized basis producing an average annual return of 15.23%. Currently, Carlisle Companies has a market capitalization of $17.03 billion. 
Buying $1000 In CSL: If an investor had bought $1000 of CSL stock 10 years ago, it would be worth $4,136.16 today based on a price of $375.79 for CSL at the time of writing.
<h3>Carlisle Companies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

In the last three months, 11 analysts have published ratings on Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $100.18, a high estimate of $121.00, and a low estimate of $73.00. This current average has increased by 4.45% from the previous average price target of $95.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1734703209_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Ultragenyx Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$121.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ultragenyx Pharmaceutical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>About Ultragenyx Pharmaceutical</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>A Deep Dive into Ultragenyx Pharmaceutical's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 42.27%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -95.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -34.27%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.46%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RARE

Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts

JMP Securities analyst Mitch Germain reiterates LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on LXP Industrial Trustto Market Perform

Eshallgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares are trading lower premarket today. The company made a strategic move by acquiring D&amp;K Asset Management (Hong Kong) Co., Ltd. and forming a partnership with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42612036/ehgo-acquired-d-k-asset-management-and-worked-with-liuli-ball-culture-to-draw-a-new-blueprint-for-" rel="noreferrer noopener">Beijing Liuliuqiu Cultural Development Co., Ltd</a>.
This acquisition marks Eshallgo&#8217;s official entry into the Tencent business ecosystem and signals a new cooperative approach in office integration services and cloud gaming, aiming to jointly explore this emerging market.
The acquisition includes two key agreements between Shenzhen Qianhai Huiying Technology Power, a subsidiary of D&amp;K Asset Management, and Tencent Technology.
The first, the &#8220;Cloud Gaming Console Product Cooperation Agreement,&#8221; focuses on developing game consoles and content through cloud gaming and streaming technologies.
The second, the &#8220;Cross-Industry Cooperation Agency Agreement,&#8221; involves joint marketing efforts targeting Tencent&#8217;s user base, with events like gaming competitions and talent shows to promote both companies and foster mutual growth.
On the same day, ESHALLGO signed a deal with Beijing Liuliuqiu for 1,000 cloud gaming consoles, leveraging Tencent&#8217;s resources to develop products supporting multiple cloud gaming services.
The consoles will integrate hardware and network resources, collaborating with platforms like Migu Quick Gaming, Tencent START, Microsoft Xcloud, and GeForce Now, driving growth in the cloud gaming industry.
ESHALLGO CEO Miao Qiwei said, &#8220;Through our in-depth cooperation, we will jointly promote the development of the integrated office and cloud gaming sectors, and delivering more convenient, efficient, and diversified service experiences for customers.&#8221;
Beijing Liuliuqiu Cultural Development added, &#8220;Partnering with ESHALLGO is a crucial step in our layout of the cloud gaming and office service sectors. ESHALLGO&#8217;s extensive experience and&nbsp;capabilities in office integration services will provide us with strong support and after-sales service guarantees.&#8221;
&#8220;At the same time, through ESHALLGO&#8217;s collaboration with&nbsp;Tencent, we will also benefit from Tencent&#8217;s powerful resources. We look forward to working hand in hand with ESHALLGO to create an even brighter future together.&#8221;
Apart from this, Eshallgo and CS Asia Opportunities Master Fund <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42612034/ehgo-announces-major-equity-financing-with-up-to-20-million-to-facilitate-its-entry-into-tencents-" rel="noreferrer noopener">disclosed a landmark equity investment</a>.
Under the agreement, CS Fund will invest up to $20 million in EHGO in tranches, acquiring up to 4.16 million shares at $4.80 per share.
This strategic partnership provides EHGO with strong financial support and fuels its business expansion, reflecting CS Fund&#8217;s confidence in the company&#8217;s future prospects.
Price Action: EHGO shares are down 9.82% at $4.50 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42613937" target="_blank" rel="noreferrer noopener">Tesla Stock Falls Over 5% During Pre-Market After Elon Musk-Led EV Giant Recalls Nearly 700,000 Vehicles</a></li>
</ul>
Image via Shutterstock.

Equities

Financing

Contracts

Small Cap

Movers

EHGO

Eshallgo Dives Into Tencent Ecosystem With Cloud Gaming Push; Reveals Up To $20 Million Investment Boost

Wells Fargo analyst Sam Reid maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Equal-Weight and lowers the price target from $165 to $145.

Wells Fargo Maintains Equal-Weight on Lennar, Lowers Price Target to $145

JMP Securities analyst Matthew Carletti maintains James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) with a Market Outperform and lowers the price target from $11 to $8.

JRVR

JMP Securities Maintains Market Outperform on James River Gr Hldgs, Lowers Price Target to $8

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Market Perform and raises the price target from $171 to $172.

Keefe, Bruyette & Woods Maintains Market Perform on Houlihan Lokey, Raises Price Target to $172

PRGO

Perrigo Reaches $98M Settlement With D&O Insurers To Resolve Coverage Dispute Over 2015-2017 Securities Litigation, Reimbursing Legal And Settlement Costs Before Year-End

As of Dec. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Paranovus Entertainment Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>)</h3>
<ul>
<li>On Sept. 13, Paranovus Entertainment Technology filed for offering of 60 million Class A ordinary shares offered by selling shareholders. The company has a <a href="https://www.benzinga.com/quote/PAVS">52-week high of $2.97</a>.</li>
<li>RSI Value: 84.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAVS Price Action: Shares of Paranovus Entertainment gained 1.4% to close at $1.42 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Duckhorn Portfolio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>)</h3>
<ul>
<li>On Dec. 5, Duckhorn Portfolio posted in-line quarterly earnings. &#8220;We are pleased to begin fiscal 2025 with strong financial performance. Our growth continues to outpace the industry as our teams remain focused on advancing our strategic initiatives,&#8221; said Deirdre Mahlan, President, CEO and Chairperson. &#8220;We believe our distinctive brands, operational excellence and market-leading performance leave us well positioned to deliver long-term growth and profitability.&#8221; The company's stock gained around 48% over the past six months and <a href="https://www.benzinga.com/quote/NAPA">has a 52-week high</a> of $11.10.</li>
<li>RSI Value: 76.78</li>
<li>NAPA Price Action: Shares of Duckhorn Portfolio climbed 0.1% to close at $11.09 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">LifeVantage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>)</h3>
<ul>
<li>On Dec. 19, Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26. The company's stock gained around 37% over the past month and has a <a href="https://www.benzinga.com/quote/LFVN">52-week high</a> of $18.41.</li>
<li>RSI Value: 71.65</li>
<li>LFVN Price Action: Shares of LifeVantage jumped 15.5% to close at $17.73 on Thursday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a></li>
</ul>

LFVN

NAPA

PAVS

Top 3 Risk Off Stocks That May Collapse This Month

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Friday.
Shares of United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) fell sharply in today's pre-market trading after the company issued fourth-quarter adjusted EPS guidance <a href="https://www.benzinga.com/news/guidance/24/12/42606023/us-steel-stock-stumbles-on-weak-q4-outlook">below analyst estimates</a>.
After the market close on Thursday, U.S. Steel said it expects to report a fourth-quarter adjusted loss of 25 cents to 29 cents per share. Fourth-quarter adjusted EBITDA is expected to come in around $150 million.
U.S. Steel shares dipped 6.5% to $29.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) dipped 19.1% to $77.10 in pre-market trading  after the company reported a default by Pharmacann on its obligations to pay rent for six of its eleven leases in December.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) declined 7.2% to $24.98 in pre-market trading.</li>
<li>Transportadora de Gas del Sur S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGS#NYSE">TGS</a>) fell 5.4% to $26.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

ARQQ

IIPR

MESO

QUBT

US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Market Perform and raises the price target from $165 to $275.

COIN

Keefe, Bruyette & Woods Maintains Market Perform on Coinbase Glb, Raises Price Target to $275

Reports Q3 revenue $22.5M, consensus $27.48M."We delivered a strong quarter of multi-year contract bookings valued up to $780 million, continuing t...

BlackSky reports Q3 EPS (66c), consensus (65c)

BlackSky (BKSY) is starting to ramp up revenues from recent contract awards and continues to work on a number of sizable new and expansion contract...

BlackSky sees FY24 revenue $102M- $118M, consensus $108.13M

In a report released today, Jeff Van Rhee from Craig-Hallum maintained a Buy rating on BlackSky Technology (BKSY – Research Report). The company's ...

BlackSky Technology (BKSY) Gets a Buy from Craig-Hallum

Blacksky Technology Inc. (BKSY) Q3 2024 Earnings Call Transcript

Blacksky Technology Inc. ( ($BKSY) ) has released its Q3 earnings. Here is a breakdown of the information Blacksky Technology Inc. presented to its...

BlackSky Technology Reports Q3 Growth and Strategic Wins

Oppenheimer analyst Timothy Horan maintained a Buy rating on BlackSky Technology (BKSY – Research Report) today and set a price target of $10.00. T...

Oppenheimer Reaffirms Their Buy Rating on BlackSky Technology (BKSY)

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Ceva (CEVA – Research Report) and BlackSky Technolog...

Analysts Offer Insights on Technology Companies: Ceva (CEVA) and BlackSky Technology (BKSY)

BlackSky (BKSY) is up 21.2%, or $1.57 to $8.97. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

BlackSky rises 21.2%

BlackSky: Next-Gen Satellites Bring Opportunities And Risks

BlackSky (BKSY) is up 5.9%, or 65c to $11.60. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

BlackSky rises 5.9%

CEVA

Press Releases

BlackSky Announces Pricing of Upsized $40 Million Public Offering of Common Stock

Penny Stocks

BlackSky Wins U.S. Navy Research Contract for Gen-3 Advanced Optical Intersatellite Links

BlackSky Announces Closing of Public Offering of Common Stock

BlackSky Wins Approximately $6 Million Contract Expansion with Legacy International Defense Sector Customer for Assured, High-Frequency Satellite Imagery Services

BlackSky Wins Five-Year NGA Luno A Contract Valued Up to $290 Million to Monitor Global Economic Activity and Military Capability

BlackSky Wins Seven-Figure Contract for Advanced Space Domain Awareness Solutions

BlackSky to Host Third Quarter 2024 Results Conference Call

LeoStella and BlackSky Selected for Space Development Agency Hybrid Acquisition for Proliferated Low-Earth Orbit program

BlackSky Reports Third Quarter 2024 Results

BlackSky to Participate at Three Upcoming Investor Conferences

Aeries Technology, Inc. - Class A Ordinary Share

Aeries Technology

Amentum Holdings

CBIZ

Clarivate

CRA Intl

Sunrise New Energy Co., Ltd - Class A Ordinary Shares

Sunrise New Energy

Falcon's Beyond Global, Inc. - Class A Common Stock

Falcons Beyond Global

Franklin Covey

Forrester Res

Graphex Group Limited American Depositary Shares, each American Depositary Share representing 20 Ordinary Shares

Graphex Gr

Huron Consulting Group Inc. - Common Stock

Huron Consulting Gr

ICF International

Innodata

LegalZoom.com

MISTRAS Group

FiscalNote Holdings, Inc. Class A common stock

FiscalNote Holdings

NV5 Global

Planet Labs

RCM Technologies

Resources Connection, Inc. - Common Stock

Resources Connection

SOS Limited American Depositary Shares, one hundred and fifty (150) Class A Ordinary Shares

Comments

BlackSky Technology

Noticias

Últimas noticias sobre BlackSky Technology (NYSE:BKSY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL